# Adversarial verification verdict — systemic_ebv_t_cell_lymphoma_childhood

## 1. DOSE LEAK
None. Grepped for mg/mcg/mg-m2/mg-kg/AUC/day-N/cycle-N/qXw/percent patterns and scanned every digit in the
file: the only numerals present are "2016" (WHO classification year), "67.4" (DeVita table number),
"12th ed." (edition number), and "interleukin-2" (receptor name) — none are doses or numbered schedules.
Clean.

## 2. UNGROUNDED CLAIMS
Verified directly against devita.txt: "Systemic EBV-positive T-cell lymphoproliferative disease of
childhood" appears exactly once (line 266711), inside the WHO 2016 lymphoid neoplasm classification list
in the Mature T- and NK-cell neoplasms section — a bare list entry, no surrounding management/treatment
prose, no staging, no regimen. So the draft agent's "0 DeVita lines grounded" claim is confirmed correct,
not an exaggeration.

Every clinical claim in the sidecar (HLH-directed therapy of etoposide + corticosteroid + calcineurin
inhibitor, parallel lymphoma-directed chemo, allogeneic HSCT as the curative step, supportive care,
monitoring markers, East Asian/Latin American predisposition, referral urgency) is explicitly tagged
inline as "(general oncology standard, not from DeVita's section on this disease)" rather than presented
as DeVita-sourced. Content-wise these are standard, uncontroversial statements consistent with published
management of this entity (HLH-94/2004-style induction, allo-HSCT for durable cure, geographic clustering
of chronic-active-EBV-driven disease) — nothing invented, no specific trial name, no fabricated statistic,
no fabricated staging system. The one item that could tempt fabrication (relapsed/refractory salvage) is
correctly and explicitly declined rather than invented.

No ungrounded-and-undisclosed claims found; disclosure is consistent throughout.

## 3. CITATION
Present. Bottom of file: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of
Oncology, 12th ed. (entity listed only in the WHO 2016 lymphoid neoplasm classification table, no
dedicated management text found)." Name-only, no page numbers, matches requirement. Also correctly notes
NCCN was not consulted/cited.

## 4. VERDICT
CLEAN (ready for R1) — with the caveat, already flagged inline by the draft agent itself, that this
disease has no DeVita-sourced management text and the whole sidecar is general-oncology-standard content
needing manual sourcing against a paediatric haem-onc/WHO-classification reference before being treated as
fully vetted. No dose leak, no fabricated regimens/trials/statistics, disclosure is honest and consistent,
citation line present and correctly scoped.
